Suchergebnisse - "Subbiah, Vivek"

PubPharm (66)

1

Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors

enthalten in: Cancer medicine | 2024

von Coleman, N. | Stephen, B. | Fu, S. | +10

2

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer : Updated Efficacy and Safety Data from the ARROW Study

enthalten in: Thyroid : official journal of the American Thyroid Association | 2024

von Subbiah, V. | Hu, M. | Mansfield, A. | +21

ErratumIn: Thyroid. 2024 Apr 16;:. - PMID 38625021

3

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

enthalten in: Cell reports. Medicine | 2023

von Nardo, M. | Gouda, M. | Nelson, B. | +7

4

Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma : A Case Series

enthalten in: Clinical lung cancer | 2023

von Fricke, J. | Wang, J. | Gallego, N. | +7

5

Clinical development and management of adverse events associated with FGFR inhibitors

enthalten in: Cell reports. Medicine | 2023

von Subbiah, V. | Verstovsek, S.

6

RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond

enthalten in: Cancer research | 2023

von Wu, J. | Subbiah, V.

CommentOn: Cancer Res. 2023 Oct 2;83(19):3237-3251. - PMID 37071495

7

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

enthalten in: Cancer discovery | 2023

von Subbiah, V. | Sahai, V. | Maglic, D. | +28

CommentIn: Cancer Discov. 2023 Sep 6;13(9):1964-1965. - PMID 37671472

8

Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer

enthalten in: JCO precision oncology | 2023

von Bhamidipati, D. | Yedururi, S. | Huse, J. | +3

9

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

10

Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care : an international mixed-method study

enthalten in: BMC medical education | 2023

von Lazure, P. | Sireci, A. | Subbiah, V. | +6

1
2
3
4
5
6
7
Nächster »
[7]